United States PCSK9 Inhibitors Market Report 2017

August 2017 | 111 pages | ID: UE43BB62AA4EN
QYResearch

Abstracts

In this report, the United States PCSK9 Inhibitors market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

• The West
• Southwest
• The Middle Atlantic
• New England
• The South
• The Midwest
• with sales (volume), revenue (value), market share and growth rate of PCSK9 Inhibitors in these regions, from 2012 to 2022 (forecast).

United States PCSK9 Inhibitors market competition by top manufacturers/players, with PCSK9 Inhibitors sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

• Amgen
• Eli Lilly
• Sanofi
• Pfizer
• Novartis
• Roche
• Merck
• Alnylam
• AstraZeneca
• Affiris
• BMS
• Ionis Pharmaceuticals
• Cyon Therapeutics
• Daiichi Sankyo

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into

• Epatha（Evolocumab）
• Praluent（Alirocumab）
• Bococizumab
• Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of PCSK9 Inhibitors for each application, including

• Clinical Application
• Drug Development
• Other

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

United States PCSK9 Inhibitors Market Report 2017

1 PCSK9 INHIBITORS OVERVIEW

1.1 Product Overview and Scope of PCSK9 Inhibitors
1.2 Classification of PCSK9 Inhibitors by Product Category
  1.2.1 United States PCSK9 Inhibitors Market Size (Sales Volume) Comparison by Type (2012-2022)
  1.2.2 United States PCSK9 Inhibitors Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  1.2.3 Epatha（Evolocumab）
  1.2.4 Praluent（Alirocumab）
  1.2.5 Bococizumab
  1.2.6 Others
1.3 United States PCSK9 Inhibitors Market by Application/End Users
  1.3.1 United States PCSK9 Inhibitors Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  1.3.2 Clinical Application
  1.3.3 Drug Development
  1.3.4 Other
1.4 United States PCSK9 Inhibitors Market by Region
  1.4.1 United States PCSK9 Inhibitors Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 The West PCSK9 Inhibitors Status and Prospect (2012-2022)
  1.4.3 Southwest PCSK9 Inhibitors Status and Prospect (2012-2022)
  1.4.4 The Middle Atlantic PCSK9 Inhibitors Status and Prospect (2012-2022)
  1.4.5 New England PCSK9 Inhibitors Status and Prospect (2012-2022)
  1.4.6 The South PCSK9 Inhibitors Status and Prospect (2012-2022)
  1.4.7 The Midwest PCSK9 Inhibitors Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of PCSK9 Inhibitors (2012-2022)
  1.5.1 United States PCSK9 Inhibitors Sales and Growth Rate (2012-2022)
  1.5.2 United States PCSK9 Inhibitors Revenue and Growth Rate (2012-2022)

2 UNITED STATES PCSK9 INHIBITORS MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States PCSK9 Inhibitors Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States PCSK9 Inhibitors Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States PCSK9 Inhibitors Average Price by Players/Suppliers (2012-2017)
2.4 United States PCSK9 Inhibitors Market Competitive Situation and Trends
  2.4.1 United States PCSK9 Inhibitors Market Concentration Rate
  2.4.2 United States PCSK9 Inhibitors Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers PCSK9 Inhibitors Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES PCSK9 INHIBITORS SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States PCSK9 Inhibitors Sales and Market Share by Region (2012-2017)
3.2 United States PCSK9 Inhibitors Revenue and Market Share by Region (2012-2017)
3.3 United States PCSK9 Inhibitors Price by Region (2012-2017)

4 UNITED STATES PCSK9 INHIBITORS SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States PCSK9 Inhibitors Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States PCSK9 Inhibitors Revenue and Market Share by Type (2012-2017)
4.3 United States PCSK9 Inhibitors Price by Type (2012-2017)
4.4 United States PCSK9 Inhibitors Sales Growth Rate by Type (2012-2017)

5 UNITED STATES PCSK9 INHIBITORS SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States PCSK9 Inhibitors Sales and Market Share by Application (2012-2017)
5.2 United States PCSK9 Inhibitors Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES PCSK9 INHIBITORS PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Amgen
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 PCSK9 Inhibitors Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Amgen PCSK9 Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Eli Lilly
  6.2.2 PCSK9 Inhibitors Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Eli Lilly PCSK9 Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Sanofi
  6.3.2 PCSK9 Inhibitors Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Sanofi PCSK9 Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Pfizer
  6.4.2 PCSK9 Inhibitors Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Pfizer PCSK9 Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Novartis
  6.5.2 PCSK9 Inhibitors Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Novartis PCSK9 Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Roche
  6.6.2 PCSK9 Inhibitors Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Roche PCSK9 Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Merck
  6.7.2 PCSK9 Inhibitors Product Category, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Merck PCSK9 Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Alnylam
  6.8.2 PCSK9 Inhibitors Product Category, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Alnylam PCSK9 Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 AstraZeneca
  6.9.2 PCSK9 Inhibitors Product Category, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 AstraZeneca PCSK9 Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Affiris
  6.10.2 PCSK9 Inhibitors Product Category, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Affiris PCSK9 Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview
6.11 BMS
6.12 Ionis Pharmaceuticals
6.13 Cyon Therapeutics
6.14 Daiichi Sankyo

7 PCSK9 INHIBITORS MANUFACTURING COST ANALYSIS

7.1 PCSK9 Inhibitors Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of PCSK9 Inhibitors

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 PCSK9 Inhibitors Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of PCSK9 Inhibitors Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES PCSK9 INHIBITORS MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States PCSK9 Inhibitors Sales Volume, Revenue Forecast (2017-2022)
11.2 United States PCSK9 Inhibitors Sales Volume Forecast by Type (2017-2022)
11.3 United States PCSK9 Inhibitors Sales Volume Forecast by Application (2017-2022)
11.4 United States PCSK9 Inhibitors Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of PCSK9 Inhibitors
Figure United States PCSK9 Inhibitors Market Size (K Units) by Type (2012-2022)
Figure United States PCSK9 Inhibitors Sales Volume Market Share by Type (Product Category) in 2016
Figure Epatha（Evolocumab） Product Picture
Figure Praluent（Alirocumab） Product Picture
Figure Bococizumab Product Picture
Figure Others Product Picture
Figure United States PCSK9 Inhibitors Market Size (K Units) by Application (2012-2022)
Figure United States Sales Market Share of PCSK9 Inhibitors by Application in 2016
Figure Clinical Application Examples
Table Key Downstream Customer in Clinical Application
Figure Drug Development Examples
Table Key Downstream Customer in Drug Development
Figure Other Examples
Table Key Downstream Customer in Other
Figure United States PCSK9 Inhibitors Market Size (Million USD) by Region (2012-2022)
Figure The West PCSK9 Inhibitors Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest PCSK9 Inhibitors Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic PCSK9 Inhibitors Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England PCSK9 Inhibitors Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US PCSK9 Inhibitors Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest PCSK9 Inhibitors Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States PCSK9 Inhibitors Sales (K Units) and Growth Rate (2012-2022)
Figure United States PCSK9 Inhibitors Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States PCSK9 Inhibitors Market Major Players Product Sales Volume (K Units) (2012-2017)
Table United States PCSK9 Inhibitors Sales (K Units) of Key Players/Suppliers (2012-2017)
Table United States PCSK9 Inhibitors Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States PCSK9 Inhibitors Sales Share by Players/Suppliers
Figure 2017 United States PCSK9 Inhibitors Sales Share by Players/Suppliers
Figure United States PCSK9 Inhibitors Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States PCSK9 Inhibitors Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States PCSK9 Inhibitors Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States PCSK9 Inhibitors Revenue Share by Players/Suppliers
Figure 2017 United States PCSK9 Inhibitors Revenue Share by Players/Suppliers
Table United States Market PCSK9 Inhibitors Average Price (USD/Unit) of Key Players/Suppliers (2012-2017)
Figure United States Market PCSK9 Inhibitors Average Price (USD/Unit) of Key Players/Suppliers in 2016
Figure United States PCSK9 Inhibitors Market Share of Top 3 Players/Suppliers
Figure United States PCSK9 Inhibitors Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers PCSK9 Inhibitors Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers PCSK9 Inhibitors Product Category
Table United States PCSK9 Inhibitors Sales (K Units) by Region (2012-2017)
Table United States PCSK9 Inhibitors Sales Share by Region (2012-2017)
Figure United States PCSK9 Inhibitors Sales Share by Region (2012-2017)
Figure United States PCSK9 Inhibitors Sales Market Share by Region in 2016
Table United States PCSK9 Inhibitors Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States PCSK9 Inhibitors Revenue Share by Region (2012-2017)
Figure United States PCSK9 Inhibitors Revenue Market Share by Region (2012-2017)
Figure United States PCSK9 Inhibitors Revenue Market Share by Region in 2016
Table United States PCSK9 Inhibitors Price (USD/Unit) by Region (2012-2017)
Table United States PCSK9 Inhibitors Sales (K Units) by Type (2012-2017)
Table United States PCSK9 Inhibitors Sales Share by Type (2012-2017)
Figure United States PCSK9 Inhibitors Sales Share by Type (2012-2017)
Figure United States PCSK9 Inhibitors Sales Market Share by Type in 2016
Table United States PCSK9 Inhibitors Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States PCSK9 Inhibitors Revenue Share by Type (2012-2017)
Figure Revenue Market Share of PCSK9 Inhibitors by Type (2012-2017)
Figure Revenue Market Share of PCSK9 Inhibitors by Type in 2016
Table United States PCSK9 Inhibitors Price (USD/Unit) by Types (2012-2017)
Figure United States PCSK9 Inhibitors Sales Growth Rate by Type (2012-2017)
Table United States PCSK9 Inhibitors Sales (K Units) by Application (2012-2017)
Table United States PCSK9 Inhibitors Sales Market Share by Application (2012-2017)
Figure United States PCSK9 Inhibitors Sales Market Share by Application (2012-2017)
Figure United States PCSK9 Inhibitors Sales Market Share by Application in 2016
Table United States PCSK9 Inhibitors Sales Growth Rate by Application (2012-2017)
Figure United States PCSK9 Inhibitors Sales Growth Rate by Application (2012-2017)
Table Amgen Basic Information List
Table Amgen PCSK9 Inhibitors Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Amgen PCSK9 Inhibitors Sales Growth Rate (2012-2017)
Figure Amgen PCSK9 Inhibitors Sales Market Share in United States (2012-2017)
Figure Amgen PCSK9 Inhibitors Revenue Market Share in United States (2012-2017)
Table Eli Lilly Basic Information List
Table Eli Lilly PCSK9 Inhibitors Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Eli Lilly PCSK9 Inhibitors Sales Growth Rate (2012-2017)
Figure Eli Lilly PCSK9 Inhibitors Sales Market Share in United States (2012-2017)
Figure Eli Lilly PCSK9 Inhibitors Revenue Market Share in United States (2012-2017)
Table Sanofi Basic Information List
Table Sanofi PCSK9 Inhibitors Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Sanofi PCSK9 Inhibitors Sales Growth Rate (2012-2017)
Figure Sanofi PCSK9 Inhibitors Sales Market Share in United States (2012-2017)
Figure Sanofi PCSK9 Inhibitors Revenue Market Share in United States (2012-2017)
Table Pfizer Basic Information List
Table Pfizer PCSK9 Inhibitors Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Pfizer PCSK9 Inhibitors Sales Growth Rate (2012-2017)
Figure Pfizer PCSK9 Inhibitors Sales Market Share in United States (2012-2017)
Figure Pfizer PCSK9 Inhibitors Revenue Market Share in United States (2012-2017)
Table Novartis Basic Information List
Table Novartis PCSK9 Inhibitors Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Novartis PCSK9 Inhibitors Sales Growth Rate (2012-2017)
Figure Novartis PCSK9 Inhibitors Sales Market Share in United States (2012-2017)
Figure Novartis PCSK9 Inhibitors Revenue Market Share in United States (2012-2017)
Table Roche Basic Information List
Table Roche PCSK9 Inhibitors Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Roche PCSK9 Inhibitors Sales Growth Rate (2012-2017)
Figure Roche PCSK9 Inhibitors Sales Market Share in United States (2012-2017)
Figure Roche PCSK9 Inhibitors Revenue Market Share in United States (2012-2017)
Table Merck Basic Information List
Table Merck PCSK9 Inhibitors Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Merck PCSK9 Inhibitors Sales Growth Rate (2012-2017)
Figure Merck PCSK9 Inhibitors Sales Market Share in United States (2012-2017)
Figure Merck PCSK9 Inhibitors Revenue Market Share in United States (2012-2017)
Table Alnylam Basic Information List
Table Alnylam PCSK9 Inhibitors Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Alnylam PCSK9 Inhibitors Sales Growth Rate (2012-2017)
Figure Alnylam PCSK9 Inhibitors Sales Market Share in United States (2012-2017)
Figure Alnylam PCSK9 Inhibitors Revenue Market Share in United States (2012-2017)
Table AstraZeneca Basic Information List
Table AstraZeneca PCSK9 Inhibitors Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure AstraZeneca PCSK9 Inhibitors Sales Growth Rate (2012-2017)
Figure AstraZeneca PCSK9 Inhibitors Sales Market Share in United States (2012-2017)
Figure AstraZeneca PCSK9 Inhibitors Revenue Market Share in United States (2012-2017)
Table Affiris Basic Information List
Table Affiris PCSK9 Inhibitors Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Affiris PCSK9 Inhibitors Sales Growth Rate (2012-2017)
Figure Affiris PCSK9 Inhibitors Sales Market Share in United States (2012-2017)
Figure Affiris PCSK9 Inhibitors Revenue Market Share in United States (2012-2017)
Table BMS Basic Information List
Table Ionis Pharmaceuticals Basic Information List
Table Cyon Therapeutics Basic Information List
Table Daiichi Sankyo Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of PCSK9 Inhibitors
Figure Manufacturing Process Analysis of PCSK9 Inhibitors
Figure PCSK9 Inhibitors Industrial Chain Analysis
Table Raw Materials Sources of PCSK9 Inhibitors Major Players/Suppliers in 2016
Table Major Buyers of PCSK9 Inhibitors
Table Distributors/Traders List
Figure United States PCSK9 Inhibitors Sales Volume (K Units) and Growth Rate Forecast (2017-2022)
Figure United States PCSK9 Inhibitors Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States PCSK9 Inhibitors Price (USD/Unit) Trend Forecast (2017-2022)
Table United States PCSK9 Inhibitors Sales Volume (K Units) Forecast by Type (2017-2022)
Figure United States PCSK9 Inhibitors Sales Volume (K Units) Forecast by Type (2017-2022)
Figure United States PCSK9 Inhibitors Sales Volume (K Units) Forecast by Type in 2022
Table United States PCSK9 Inhibitors Sales Volume (K Units) Forecast by Application (2017-2022)
Figure United States PCSK9 Inhibitors Sales Volume (K Units) Forecast by Application (2017-2022)
Figure United States PCSK9 Inhibitors Sales Volume (K Units) Forecast by Application in 2022
Table United States PCSK9 Inhibitors Sales Volume (K Units) Forecast by Region (2017-2022)
Table United States PCSK9 Inhibitors Sales Volume Share Forecast by Region (2017-2022)
Figure United States PCSK9 Inhibitors Sales Volume Share Forecast by Region (2017-2022)
Figure United States PCSK9 Inhibitors Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources